Back

MoonLake keeps Buy rating with $33.00 target as Liquidia retains Hold

Verifying
  • LifeSci Capital maintained Buy on MoonLake and reiterated Hold on Liquidia.
  • MoonLake closed at $11.70; Liquidia closed at $30.26 last Wednesday.
  • MoonLake coverage includes sonelokimab filings and positive Phase 3 psoriatic arthritis results.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.